The total number of shares in Flerie AB (publ) (the “Company”) as of 29 May 2026 amounts to 95,110,280, all of which are ordinary shares. There are no shares issued of series C. The total number of votes in the Company as of 29 May 2026 amounts to 95,110,280.
The change in the number of shares and votes in the Company is due to the issuance of 11,888,785 new ordinary shares through the bonus issue resolved by the annual general meeting on 26 March 2026.
For more information, please contact:
Ted Fjällman, CEO of Flerie
E-mail: ir@flerie.com
Telephone: +46 (0)76 600 89 26
This information is information that Flerie is obliged to make public pursuant to Chapter 4, Section 9 of the Financial Instruments Trading Act (SFS 1991:980). The information was submitted for publication on 29 May 2026, at 11:00 CEST.
About Flerie
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com.